- Home
- IMRN vs AYTU Comparison
IMRN vs AYTU Comparison
Compare IMRN & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- AYTU
- Stock Information
- Founded
- IMRN 1994
- AYTU N/A
- Country
- IMRN Australia
- AYTU United States
- Employees
- IMRN N/A
- AYTU N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- AYTU Health Care
- Exchange
- IMRN Nasdaq
- AYTU Nasdaq
- Market Cap
- IMRN 15.0M
- AYTU 15.0M
- IPO Year
- IMRN N/A
- AYTU N/A
- Fundamental
- Price
- IMRN $2.25
- AYTU $2.24
- Analyst Decision
- IMRN Strong Buy
- AYTU
- Analyst Count
- IMRN 1
- AYTU 0
- Target Price
- IMRN $5.00
- AYTU N/A
- AVG Volume (30 Days)
- IMRN 7.2K
- AYTU 32.2K
- Earning Date
- IMRN 10-22-2024
- AYTU 11-12-2024
- Dividend Yield
- IMRN N/A
- AYTU N/A
- EPS Growth
- IMRN N/A
- AYTU N/A
- EPS
- IMRN N/A
- AYTU N/A
- Revenue
- IMRN $3,271,194.00
- AYTU $81,002,000.00
- Revenue This Year
- IMRN N/A
- AYTU N/A
- Revenue Next Year
- IMRN N/A
- AYTU N/A
- P/E Ratio
- IMRN N/A
- AYTU N/A
- Revenue Growth
- IMRN 171.67
- AYTU N/A
- 52 Week Low
- IMRN $1.48
- AYTU $2.11
- 52 Week High
- IMRN $5.96
- AYTU $3.50
- Technical
- Relative Strength Index (RSI)
- IMRN 32.37
- AYTU 40.89
- Support Level
- IMRN $2.66
- AYTU $2.11
- Resistance Level
- IMRN $2.73
- AYTU $2.44
- Average True Range (ATR)
- IMRN 0.19
- AYTU 0.14
- MACD
- IMRN -0.06
- AYTU -0.02
- Stochastic Oscillator
- IMRN 24.04
- AYTU 17.57
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.